MiniReview |
From the Department of Physiology, College of Medicine (C.H.G., M.K.R.) and Department of Pharmacodynamics, College of Pharmacy (M.J.K.), University of Florida, Gainesville, Fla.
Correspondence to Craig H. Gelband, PhD, Department of Physiology, University of Florida College of Medicine, PO Box 100274, Gainesville, FL 32610-0274. E-mail gelband{at}phys.med.ufl.edu
AbstractSystemic hypertension is a pathophysiological state that is manifested as high blood pressure and is a major risk factor for stroke, ischemic heart disease, peripheral vascular disease, and progressive renal damage. Pulmonary hypertension occurs in 3 distinct forms: primary pulmonary hypertension, pulmonary hypertension of the newborn, or secondary pulmonary hypertension attributable to a variety of lung and cardiovascular diseases. This review discusses the use of gene therapy in the control of systemic and pulmonary hypertension. Overexpression of vasodilator genes as well as antisense knockdown of vasoconstrictor genes has been successfully used in animal models of both forms of hypertension. Furthermore, the use of viral vectors to deliver these constructs has achieved long-term control of hypertension. The successful establishment of gene therapy techniques in the animal models of hypertension coupled with the anticipated advances in the genetic aspects of this disease would make it highly feasible to attempt gene delivery in the control of human hypertension.
Key Words: antisense gene therapy hypertension renal and cardiac pathophysiology renin-angiotensin system
This article has been cited by other articles:
![]() |
J.-C. Richard, Z. Zhou, D. E. Ponde, C. S. Dence, P. Factor, P. N. Reynolds, G. D. Luker, V. Sharma, T. Ferkol, D. Piwnica-Worms, et al. Imaging Pulmonary Gene Expression with Positron Emission Tomography Am. J. Respir. Crit. Care Med., May 1, 2003; 167(9): 1257 - 1263. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Chu, S. Iida, D. D. Lund, R. M. Weiss, G. F. DiBona, Y. Watanabe, F. M. Faraci, and D. D. Heistad Gene Transfer of Extracellular Superoxide Dismutase Reduces Arterial Pressure in Spontaneously Hypertensive Rats: Role of Heparin-Binding Domain Circ. Res., March 7, 2003; 92(4): 461 - 468. [Abstract] [Full Text] [PDF] |
||||
![]() |
K Taylor and J Stein Dyslexia and familial high blood pressure: an observational pilot study Arch. Dis. Child., January 1, 2002; 86(1): 30 - 33. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. S. Pachori, M. J. Huentelman, S. C. Francis, C. H. Gelband, M. J. Katovich, and M. K. Raizada The Future of Hypertension Therapy: Sense, Antisense, or Nonsense? Hypertension, February 1, 2001; 37(2): 357 - 364. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. C. FRANCIS, M. K. RAIZADA, A. A. MANGI, L. G. MELO, V. J. DZAU, P. R. VALE, J. M. ISNER, D. W. LOSORDO, J. CHAO, M. J. KATOVICH, et al. Genetic targeting for cardiovascular therapeutics: are we near the summit or just beginning the climb? Physiol Genomics, December 21, 2001; 7(2): 79 - 94. [Abstract] [Full Text] [PDF] |
||||
|
Circulation Research Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2000 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |